Probi AB (publ)

Stockholm Stock Exchange PROB.ST

Probi AB (publ) EBITDA for the year ending December 31, 2023: USD 11.41 M

Probi AB (publ) EBITDA is USD 11.41 M for the year ending December 31, 2023, a -8.74% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Probi AB (publ) EBITDA for the year ending December 31, 2022 was USD 12.50 M, a -34.09% change year over year.
  • Probi AB (publ) EBITDA for the year ending December 31, 2021 was USD 18.97 M, a -15.72% change year over year.
  • Probi AB (publ) EBITDA for the year ending December 31, 2020 was USD 22.51 M, a 18.23% change year over year.
  • Probi AB (publ) EBITDA for the year ending December 31, 2019 was USD 19.04 M, a 6.63% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
Stockholm Stock Exchange: PROB.ST

Probi AB (publ)

CEO Ms. Anita Johansen
IPO Date Dec. 2, 2004
Location Sweden
Headquarters Ideongatan 1A
Employees 157
Sector Health Care
Industries
Description

Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.

Similar companies

BIOT.ST

Biotage AB (publ)

USD 11.98

-2.51%

RAY-B.ST

RaySearch Laboratories AB (publ)

USD 20.58

0.68%

VITR.ST

Vitrolife AB (publ)

USD 18.25

2.79%

CEVI.ST

CellaVision AB (publ)

USD 18.76

3.89%

BIOG-B.ST

BioGaia AB (publ)

USD 9.75

-0.95%

StockViz Staff

January 15, 2025

Any question? Send us an email